These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21270195)

  • 1. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
    Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
    Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
    Noguchi Y; Esaki H; Murayama A; Sugioka M; Koyama A; Tachi T; Teramachi H
    Eur J Clin Pharmacol; 2020 Feb; 76(2):299-304. PubMed ID: 31822955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016.
    Yi H; Lee JH; Shin JY
    Yonsei Med J; 2019 Feb; 60(2):200-207. PubMed ID: 30666842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
    Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
    Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
    Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
    Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
    Rahman MM; Scalese MJ; Hansen RA
    Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.
    Wang CY; Fu SH; Yang RS; Hsiao FY
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):500-506. PubMed ID: 30724413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
    Chou HC; Chen WW; Hsiao FY
    Drug Saf; 2014 Jul; 37(7):521-8. PubMed ID: 24859164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®.
    Carnovale C; Mazhar F; Arzenton E; Moretti U; Pozzi M; Mosini G; Leoni O; Scatigna M; Clementi E; Radice S
    Expert Opin Drug Saf; 2019 Nov; 18(11):1099-1108. PubMed ID: 31519110
    [No Abstract]   [Full Text] [Related]  

  • 16. Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study.
    Shih CJ; Lee YJ; Lo YH; Kuo SC; Ou SM; Chen YT
    Mayo Clin Proc; 2016 Jul; 91(7):867-72. PubMed ID: 27236426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
    Huang L; Liu Y; Li H; Huang W; Geng R; Tang Z; Jiang Y
    Int J Med Sci; 2021; 18(9):1946-1952. PubMed ID: 33850463
    [No Abstract]   [Full Text] [Related]  

  • 19. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
    BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.
    Yabe D; Kuwata H; Kaneko M; Ito C; Nishikino R; Murorani K; Kurose T; Seino Y
    Diabetes Obes Metab; 2015 Apr; 17(4):430-4. PubMed ID: 25146418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.